about
Differential activation of CC chemokine receptors by AOP-RANTESPlatelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptorHIV-1 Tat protein mimicry of chemokinesCloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cellsScreening of the 'Pathogen Box' identifies an approved pesticide with major anthelmintic activity against the barber's pole wormTools and Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand Convergence in Malaria?Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.Structural Basis for Selective Inhibition of Mycobacterium tuberculosis Protein Tyrosine Phosphatase PtpBThe three-dimensional solution structure of RANTESOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondInhibition of phosphomannose isomerase by mercury ions.Purification, cDNA cloning and heterologous expression of human phosphomannose isomeraseThe BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivityThe platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptorsChemokine and chemokine receptor mRNA expression in human plateletsCloning of a full-length cDNA encoding the neutrophil-activating peptide ENA-78 from human plateletsRANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosisNew developments in anti-malarial target candidate and product profilesA key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shockThe open access malaria box: a drug discovery catalyst for neglected diseasesAnticancer properties of distinct antimalarial drug classesOrally active antischistosomal early leads identified from the open access malaria boxOpen source drug discovery - a limited tutorialStructure of immunoglobulin G by scanning tunnelling microscopy.Natural products as starting points for future anti-malarial therapies: going back to our roots?Assessing the anthelmintic activity of pyrazole-5-carboxamide derivatives against Haemonchus contortus.Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus.Chemokine receptors and their role in leukocyte activation.Repositioning: the fast track to new anti-malarial medicines?Chemokine receptors and their antagonists in allergic lung disease.Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokinesRole of cysteine62 in DNA recognition by the P50 subunit of NF-kappa BRole of CCL5 (RANTES) in viral lung disease.Strategies for chemokine antagonists as therapeutics.The virus-encoded chemokine vMIP-II inhibits virus-induced Tc1-driven inflammationMulti-faceted strategies to combat disease by interference with the chemokine system.A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments.Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4.The global pipeline of new medicines for the control and elimination of malariaGlycosaminoglycan analogs as a novel anti-inflammatory strategy
P50
Q22253325-DC76B2D9-492E-4E62-AFA7-6A9BE9E6653FQ24321786-5D3F7F23-9400-470B-A7DA-88ECEE1C2A88Q24644383-6DC50348-CFA3-4B6D-9AAB-2E0DBED8FD6FQ24652902-DD28BBAF-2C3A-46B7-9413-3B6A0D59DEECQ26741549-FD6DED43-4313-47F6-908F-EE9C0F24C8ADQ26765029-F044101B-3313-432C-9838-DECAAF088A59Q27324132-02D482D3-5134-4982-8C92-102B4DA8DCC5Q27644471-53755055-03DD-4B7E-B6C6-9793C43FED9EQ27729432-B844EDEE-B7C6-429D-9DF3-C04EA0A2AE28Q27826351-35DE101B-4574-4A1D-B7A2-4ABA5BD6154CQ27930213-0C0EBD75-2E9C-4DEA-AC13-0CADA522793BQ28114884-606F7CFA-4B10-400E-8B41-05D5E02F2B16Q28140341-D6B6D6F5-1239-4F67-AA9B-DA0A31F106F5Q28145360-6CCB11B4-D9F1-43A4-B976-445AB3DE7E3CQ28274492-0AE6F79F-A646-4959-B3AC-90F67B1ADD10Q28305812-BF735663-8F5F-42F0-9F40-F0F1F38CD7F5Q28307643-409B0E03-28D5-4F96-B8B1-23D3D3B3070CQ28468598-7100330F-5BDB-4049-94E4-44E9A5DC85F4Q28508967-977EA209-4395-4C7D-A4E7-5CA92F22A98DQ28533977-238E924A-AB98-44CB-9402-AB92C990CC0BQ28538116-428E96B7-2CCD-4C5D-AE03-55AB93A982BCQ28538566-C86BFD82-091F-4450-AD61-3857A3D99376Q28660808-72DCB999-F1CC-476D-B574-207A54B0C299Q30374834-BB7669A6-74DA-4714-ADCF-7B311596B793Q30396384-EAE73C18-D088-4D74-8128-46E74C5BE286Q30854256-8BB2674B-68F8-45C5-8959-A3246EB573AFQ33291297-6211AC7F-E0BF-40B9-B7FF-0A98AE275D63Q33538287-D85C1418-E867-4BC8-9245-E945164A6998Q33612012-077755FA-0036-4D0C-805E-8D816E27646DQ33713498-7EADD3D1-63C5-43C8-99E3-A1F4868DC8A2Q34762409-CA9AC154-80C7-41F8-8435-4D7EB03847C0Q34979723-BEAF39B9-A279-4024-AB4C-491F85966040Q35024052-B3CFDDB3-95A9-417A-92E8-5B79E6D43865Q35031917-9AD73D29-C036-4AE4-9C94-C6300480EF5AQ35149350-02A22EED-00DA-4356-B1FD-ACA50FE6CF76Q36113426-7AA31FFA-787C-4B15-8C27-8080D9179080Q36137064-73BDABB5-19A0-4132-99EF-F02E0AB33420Q36276570-2D9863CA-B01A-46AD-BA6A-C0B99867F2CAQ36320249-7945732B-B591-420D-8B5B-1F046D9E58D5Q36321143-5E425C4A-7736-4558-8A43-76D1A258A11D
P50
subject
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Timothy N C Wells
@ast
Timothy N C Wells
@en
Timothy N C Wells
@es
Timothy N C Wells
@nl
Timothy N C Wells
@sl
type
label
Timothy N C Wells
@ast
Timothy N C Wells
@en
Timothy N C Wells
@es
Timothy N C Wells
@nl
Timothy N C Wells
@sl
prefLabel
Timothy N C Wells
@ast
Timothy N C Wells
@en
Timothy N C Wells
@es
Timothy N C Wells
@nl
Timothy N C Wells
@sl
P1006
P214
P244
P1006
P106
P1153
7202039102
P21
P214
P244
P31
P496
0000-0001-9796-847X
P735
P7859
lccn-n99803868